New drug aims to stop bleeding in rare blood disorder

This early-phase study tests a new drug called BT200 in 4-6 adults with type 2B von Willebrand disease who have low platelets and a history of bleeding. The drug is designed to raise von Willebrand factor and platelet levels, which may lower the risk of bleeding. Participants receive both BT200 and a placebo at different times to compare effects.